A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study

INTRODUCTION: Timely matching of patients to beneficial targeted therapy is an unmet need in rheumatoid arthritis (RA). A molecular signature response classifier (MSRC) that predicts which patients with RA are unlikely to respond to tumor necrosis factor-α inhibitor (TNFi) therapy would have wide cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Stanley, Wells, Alvin F., Curtis, Jeffrey R., Dhar, Rajat, Mellors, Theodore, Zhang, Lixia, Withers, Johanna B., Jones, Alex, Ghiassian, Susan D., Wang, Mengran, Connolly-Strong, Erin, Rapisardo, Sarah, Gatalica, Zoran, Pappas, Dimitrios A., Kremer, Joel M., Saleh, Alif, Akmaev, Viatcheslav R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214458/
https://www.ncbi.nlm.nih.gov/pubmed/34148193
http://dx.doi.org/10.1007/s40744-021-00330-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214458/
https://www.ncbi.nlm.nih.gov/pubmed/34148193
http://dx.doi.org/10.1007/s40744-021-00330-y

Ejemplares similares